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Mutations in the gene for guanylate cyclase–activating protein-1 (GCAP1) (GUCA1A) have been associated with
autosomal dominant cone dystrophy (COD3). In the present study, a severe disease phenotype in a large white
family was initially shown to map to chromosome 6p21.1, the location of GUCA1A. Subsequent single-stranded
conformation polymorphism analysis and direct sequencing revealed an A464G transition, causing an E155G
substitution within the EF4 domain of GCAP1. Modeling of the protein structure shows that the mutation eliminates
a bidentate amino acid side chain essential for Ca2+ binding. This represents the first disease-associated mutation
in GCAP1, or any neuron-specific calcium-binding protein within an EF-hand domain, that directly coordinates
Ca2+. The functional consequences of this substitution were investigated in an in vitro assay of retinal guanylate
cyclase activation. The mutant protein activates the cyclase at low Ca2+ concentrations but fails to inactivate at
high Ca2+ concentrations. The overall effect of this would be the constitutive activation of guanylate cyclase in
photoreceptors, even at the high Ca2+ concentrations of the dark-adapted state, which may explain the dominant
disease phenotype.
Introduction
Autosomal dominant cone dystrophies are a type of he-
reditary macular degeneration characterized by a pro-
gressive dysfunction of the photopic system, with pres-
ervation of scotopic function. They occur in the
population with a frequency of ∼1/10,000 (Small et al.
1996). The disease presents as the phenotypic triad of
loss of color vision, photophobia, and reduced central
visual acuity and is distinguished from the cone-rod dys-
trophies, in which some loss of peripheral vision also
occurs. Cone dystrophy is a genetically heterogeneous
disorder, with phenotype linked to loci on 17p12-13
(Balciuniene et al. 1995; Small et al. 1996), Xp21.1-
p11.3 (Jacobsen et al. 1989), 6q25-q26 (retinal cone
dystrophy 1 [MIM 180020]), and 6p21.1 (Payne et al.
1998). In the case of 6p21.1, mutations have been iden-
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tified in GUCA1A (COD3 [MIM 602093 and 600364])
(Payne et al. 1998; Downes et al. 2001), the gene that
encodes guanylate cyclase–activating protein-1 (GCAP1).
GCAP1 is a key component in the recovery of photo-
receptor cells to the dark-adapted state after exposure
to a light stimulus. This recovery process is mediated
via a change in intracellular free calcium ions in re-
sponse to a decrease in the level of cyclic guanosine
monophosphate (cGMP); both calcium ions and cGMP
are fundamental secondary messengers in photorecep-
tors. Several mechanisms, highly conserved across spe-
cies, have developed to maintain a low [Ca2]free within
photoreceptors. In the dark-adapted state, the [Ca2]free
in photoreceptor outer segments rises to ∼500 nM be-
cause of the influx of Ca2 through open cGMP-gated
Na/Ca2 channels (Dizhoor and Hurley 1999). Ex-
posure to light leads to the hydrolysis of cGMP by phos-
phodiesterase (via a rhodopsin-mediated cascade) and
to a subsequent decrease in [Ca2]free to ∼30 nM because
of the continued efflux of Ca2 through light-indepen-
dent Na/K/Ca2 exchangers (Baylor 1996; Koutalos
and Yau 1996; Pugh et al. 1996; Sampath et al. 1998).
This decrease in [Ca2]free stimulates an increase in
cGMP, synthesized by two distinct retina-specific iso-
forms of guanylate cyclase (RetGC1 and RetGC2), in
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a feedback mechanism vital to the process of light ad-
aptation and the recovery of the dark-adapted state
(Hayashi and Yamazaki 1991; Shyjan et al. 1992; Di-
zhoor et al. 1994; Garbers and Lowe 1994; Goraczniak
et al. 1994; Lowe et al. 1995; Sitaramayya et al. 1995;
Yang et al. 1995; Pugh et al. 1997).
The RetGCs are not directly sensitive to changes in
[Ca2]free; calcium exerts its regulatory effect via spe-
cialized calcium-binding proteins known as guanylate
cyclase–activating proteins (GCAPs) (Dizhoor et al.
1994; Palcewski et al. 1994; Dizhoor et al. 1995; Gor-
czyza et al. 1995; Lowe et al. 1995; Haeseleer et al.
1999). Three mammalian isoforms have been identified,
GCAP1 (Palczewski et al. 1994), GCAP2 (Dizhoor et
al. 1995; Gorczyca et al. 1995) and GCAP3 (Haeseleer
et al. 1999). GCAPs belong to a subgroup of the neuron-
specific calcium-binding proteins (NCBPs), which in-
cludes recoverin. All NCBPs incorporate four variably
functional repeats of the EF-hand domain (Polans et al.
1996), a helix-loop-helix structural domain with a se-
lectively high affinity for Ca2 binding (kD !10
5 M)
(Nockolds et al. 1972). In the case of the GCAPs, only
EF2, EF3, and EF4 are functional. Numerous studies
have demonstrated that the GCAPs function to mediate
the calcium-sensitive synthesis of cGMP by RetGC
(Koch and Stryer 1988; Pittler and Baehr 1991; Dizhoor
et al. 1994, 1995; Palczewski et al. 1994; Goryczya et
al. 1995; Lowe et al. 1995; Duda et al. 1996; Frins et
al. 1996; Pugh et al. 1997; Rudnicka-Nawrot et al.
1998; Haeseleer et al. 1999), activating the cyclase at
[Ca2]free !100 nM and inhibiting the cyclase at [Ca
2]free
1500 nM, concentrations characteristic of light- and
dark-adapted photoreceptors, respectively. This distin-
guishes the GCAPs from other calcium-binding pro-
teins, which typically activate effector proteins in their
calcium-loaded forms.
The genes for human GCAP1 and GCAP2 reside in
a tail-to-tail array on chromosome 6p21.1 (Subbaraya
et al. 1994; Surguchov et al. 1997; Howes et al. 1998)
and share a common four-exon/three-intron arrange-
ment. GCAP3 shares the same exon/intron arrangement
but has been localized to chromosome 3q13.1 (Hae-
seleer et al. 1999). This suggests that the three GCAP
genes arose as a result of the duplication and translo-
cation of a common ancestral gene. All three proteins
have been localized to the retina in various species, with
GCAP1 present in higher concentrations in cone than
in rod outer segments (Gorczyca et al. 1995; Cuenca et
al. 1998). GCAP2 is localized to rods (Dizhoor et al.
1995), cone inner segments (Otto-Bruc et al. 1997), and
layers of the inner retina (Cuenca et al. 1998; Howes
et al. 1998).
To date, two mutations have been identified in
GCAP1. A Y99C substitution causes a severe cone dys-
trophy (Payne et al. 1998), and a P50L substitution is
associated with a more variable phenotype, ranging
from mild cone dystrophy to pronounced cone-rod dys-
trophy (Downes et al. 2001). In the present article, we
report the clinical and genetic characteristics of a family
with a severe form of autosomal dominant cone dys-
trophy that segregates a novel E155G mutation in
GCAP1 (GUCA1A). We also describe the functional
consequences of this mutation and the ability of the
mutant protein to regulate RetGC activity in response
to calcium ion changes. This represents the first disease-
causing mutation found in the highly conserved 12-res-
idue Ca2-binding motif of an EF hand.
Material and Methods
Subjects
Approval from the Institutional Review Board of the
Cleveland Clinic Foundation was obtained for the pre-
sent study, and informed consent was obtained from all
patients. Of 67 individuals at risk for a dominantly in-
herited cone dystrophy in a large white kindred, 33 were
found to be affected.
Clinical and Functional Investigations
A visual history was obtained from all patients, and
best corrected visual acuities were assessed. Ophthal-
moscopic examination was performed on all patients,
and fluorescein angiography and electroretinography
were performed on one patient. Blood samples were ob-
tained by venipuncture.
After initial dark adaptation, electroretinograms
(ERGs) were made, using a bipolar Burian-Allen contact
lens electrode, to record response to stimuli presented
within an LKC ganzfeld. The response was differentially
amplified (band-pass: 0.3–500 Hz), averaged, and stored
using an LKC UTAS E-2000 signal-averaging system.
Responses were initially recorded from the dark-adapted
eyes, using a low-intensity (24-dB attenuation) and
high-intensity (0-dB attenuation) strobe flash. A steady
adapting field was then used to desensitize the rod re-
sponse. After a 7-min period of light adaptation (Peachey
et al. 1989), high-intensity responses were superimposed
on the adapting field.
Genetic Linkage and Mutation Screening
DNA was extracted from blood samples, and genetic
linkage was assessed using microsatellite marker
D6S1017, which is linked to the GCAP1 locus. Linkage
analysis was performed under the assumption that the
disease-allele frequency is .0001 and that the mode of
inheritance is autosomal dominant, with a penetrance
of 90%. Each of the four exons of the GCAP1 gene was
amplified by PCR and analyzed by SSCP, using the
method of Orita et al. (1989). Mutational screening was
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Figure 1 Autosomal dominant inheritance of cone dystrophy. Individuals are identified by generation and pedigree number; squares
indicate males, and circles indicate females. Blackened symbols indicate affected individuals; open symbols, indicate unaffected individuals.
then performed by direct sequencing of PCR-amplified
DNA fragments corresponding to each exon of the gene.
Each fragment was sequenced on both strands. Sequenc-
ing was performed with the Taq DyeDeoxy Terminator
Cycle Sequencing Kit (Applied Biosystems), according to
the manufacturer’s instructions.
Mutagenesis of GCAP1 and Expression in Escherichia
coli
An E155G point mutation was introduced into human
wild-type GCAP1, using a GeneEditor site-directed mu-
tagenesis kit (Promega) and the following mutagenesis
primer: 5′-CT TCC CTG GAA GGG TTT ATA GAG
G-3′. The wild-type GCAP1 clone used for the muta-
genesis carried an artificial E6S substitution to facilitate
N-myristoylation of the protein, which has been found
to be necessary for the activation of RetGC1 by GCAP1
(Frins et al. 1996). The mutated sequence was cloned in
pET3a (Novagen) and expressed in E. coli strain
BL21(DE3)pBBLysS (Newbold et al. 2001). This strain
carries the pBBLysS plasmid-encoding yeast N-myris-
toyltransferase, which is coexpressed with the GCAP1
and effects N-terminal modification of the latter protein.
Conditions for the expression and subsequent purifica-
tion of the wild-type and E155G proteins were as de-
scribed by Newbold et al. (2001).
Assay of RetGC1 Activation
Human RetGC1 was produced in HEK 293T cells
transiently transfected with a pRC.CMV RetGC1 con-
struct (provided by J. B. Hurley) and isolated in the form
of a membrane preparation, as described by Wilkie et
al. (2000). Measurement of guanylate cyclase activity
was conducted in a radioassay with the use of a[32P]GTP,
according to the method of Dizhoor et al. (1995), which
was modified as described by Wilkie et al. (2000). Basal
activity and activity stimulated by wild-type and mutant
GCAP1 were measured in reaction buffers containing a
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Figure 2 Clinical evaluation. A, Fundus photograph from a patient (IV:37) with cone dystrophy, aged 26 years, with visual acuity 20/
200, showing central macular pigmentary changes. B, ERGs recorded from the left (OS) and right (OD) eye of patient V:6 (aged 43 years),
showing responses to ganzfeld stimuli (times of flash indicated by vertical bars) presented to the dark-adapted eye with a low-intensity strobe
flash (top row) and with a high-intensity strobe flash (middle row) and to the light-adapted eye with a high-intensity strobe flash (bottom row).
Two successive responses are shown for each stimulus condition. Note that the ERG of the light-adapted eye (cone) is diminished below the
normal range, whereas responses of the dark-adapted eye (rod-dominated) fall within normal limits.
Figure 3 Alignment of the three functional EF-hand domains in GCAP1. The a-helix and loop regions of the domain are identified above
the sequences. Residues in the loop that coordinate the Ca2 ion are marked with an asterisk. The invariant Glu residues at position 12 of each
Ca2-binding loop (E75, E111, and E155) are highlighted in bold. The positions of the E155G mutation in EF4 present in our pedigree and of
the previously reported Y99C mutation in EF3 are boxed.
range of [Ca2]free, formulated according to the method
of Tsien and Pozzan (1989).
Results
Clinical Findings
Clinical evaluations of a large kindred of five gener-
ations revealed an autosomal dominant pattern of in-
heritance (fig. 1). On the basis of the presence of de-
creased visual acuity, abnormalities of color vision, and
macular lesions, 33 of 67 individuals at risk for inher-
iting the disease were found to be affected. The age at
onset of decreased visual acuity, color vision defects, and
photophobia is 8–24 years, with a mean of 16 years.
Visual loss progresses, during the next two decades, until
visual acuity is between 20/200 and 20/400. Fundus ex-
amination revealed a central macular lesion with pig-
mentary changes (fig. 2A)
Figure 2B presents ERGs recorded, from the two eyes
of an affected patient (V:6), under standard stimulation
and recording conditions. In each stimulation condition,
two successive responses are overlain to demonstrate re-
producibility. The top row shows the rod-mediated
ERGs obtained from a dim flash presented to the dark-
adapted eye. The amplitude of the b-wave falls within
the range of normal. The middle row shows the response
of the dark-adapted eye to a high-intensity stimulus
flash. The negative-polarity a-wave also falls within the
normal range, and the positive b-wave was at or slightly
below the normal range. The bottom row shows the
response obtained under light-adapted conditions to iso-
late the cone response. For both eyes, the amplitude of
the cone ERG falls well below the lower limit of the
normal range.
Genetic Analysis
An initial genotype analysis with marker D6S1017
yielded a significant LOD score of 3.3 at a recombination
fraction of 0.1, indicating positive linkage to the GCAP1
locus. SSCP analysis, followed by direct sequencing, re-
vealed an ArG transition in nucleotide 464, resulting
in an E155G amino acid substitution in the EF4 domain
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Figure 4 GCAP1 titrations of RetGC1 activity with wild-type GCAP1 (blackened circles), E155G mutant (blackened triangles) and an
equimolar mixture of wild-type and E155G mutant (open squares). Curves were fitted to the data points on the basis of the relation vp
, where Km
app[GCAP1] is the GCAP1 concentration required for half maximal activation and whereapp[GCAP1]V /(K [GCAP1] [GCAP1])max m
Vmax is the maximum specific activation. Values of Vmax and Km
app[GCAP1] are derived from the fitted curves are given in table 1.
Table 1
Kinetic Parameters Vmax and Km
app[GCAP1] for Activation
of RetGC1 by Wild-Type and E155G Mutant GCAP1
GCAP1 Vmax  SE
a Km
app[GCAP1]  SEb
Wild type 4350  120 0.738  0.106
Wild type/E155Gc 4219  293 1.103  0.318
E155G 3955  320 1.688  0.453
a Vmax measured as picomoles of cGMP per minute per
milligram of protein.
b Km measured as micromoles.
c Equimolar mixture.
of GCAP1 (fig. 2). This change segregated with the dis-
ease phenotype in the entire family (fig. 1), with a max-
imum LOD score of 7.0, and it was not found in 200
normal control subjects. The primary sequences of the
three functional EF hands in GCAP1 identifying the
E155G mutation present in the pedigree is shown in
figure 3.
Functional Analysis
An E155G substitution was introduced into wild-type
human GCAP1 by site-directed mutagenesis. This was
cloned in the vector pET3a and expressed in E. coli cells.
The GCAP1 protein was isolated in a cytosolic extract
from the cells and purified in a single-column gel-filtra-
tion procedure, as described by Newbold et al. (2001).
The purified protein was assayed for its ability to activate
RetGC1, as described elsewhere (Dizhoor et al. 1995;
Wilkie et al. 2000). A titration of RetGC1 activity
against increasing concentrations of GCAP1 in the pres-
ence of a high substrate (GTP) concentration demon-
strated that the initial rate of cGMP formation reached
a maximum (saturated) value at high GCAP1 concen-
trations, with both wild-type and E155G GCAP1 (fig.
4). The maximum specific activation (Vmax) obtained
with the mutant GCAP1 was slightly lower than that
obtained with the wild type. However, the GCAP1 con-
centration required for half-maximal activation (Km
app[GCAP1]) was approximately double that of the wild
type (table 1), indicating a lower apparent affinity of
RetGC1 for mutant than for wild-type GCAP1. An equi-
molar mixture of wild-type and mutant protein, repre-
senting the situation in an individual heterozygous for
the mutation, yielded intermediate results.
In wild-type GCAP1, binding of Ca2 ions to the three
EF hands regulates its ability to activate RetGC1. Thus,
at [Ca2]free 100 nM, RetGC1 is activated by GCAP1
(Dizhoor et al. 1994; Gorczyca et al. 1994), but at mi-
cromolar concentrations it is inhibited (Rudnicka-Na-
wrot et al. 1998). Ca2 titrations of RetGC1 activity in
the presence of wild-type and mutant GCAP1 are shown
in figure 5. With wild-type GCAP1, the [Ca2]free for half-
maximal activity was estimated to be ∼350 nM. With
mutant GCAP1, however, the curve shows very little
inhibition of activity at levels 1350 nM. Even at 1 mM
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Figure 5 Ca2 sensitivity of activation of wild-type RetGC1 by
wild-type and mutant GCAP1. A, Activation by wild-type (blackened
circles) and E155G mutant (open circles) GCAP1 and by an equimolar
mixture of wild-type and E155Gmutant (open triangles).B,Activation
by wild-type (blackened circles) and Y99C mutant (open circles)
GCAP1. Guanylate cyclase activity was determined inmembrane prep-
arations expressing RetGC1 activity stimulated with 8 mM GCAP1 in
all cases. Results are presented as percentage of maximum RetGC1
activation (maximum RetGC1 activity minus basal activity in absence
of GCAP1).
(generally regarded as above the maximumphysiological
[Ca2]free in photoreceptor cells), almost 70% of maxi-
mal activity persists, compared with ∼10%with thewild
type. When an equimolar mixture of wild-type and mu-
tant GCAP1 is used, activity at [Ca2]free levels 1350 nM
is again maintained; at 1 mM, almost 50% of maximal
activity persists. Thus, the effect of the mutation is to
maintain high levels of cyclase activity over the whole
physiologically relevant range of [Ca2]free. This effect is
dominant, in that it persists even in the presence of wild-
type GCAP1 protein.
The Y99C mutation in GCAP1 has been shown to
result in a similar constitutive activation of RetGC1 at
high [Ca2]free (Dizhoor et al. 1998; Sokal et al. 1998).
Comparison of the magnitude of the effects of the two
mutations on RetGC activity (fig. 5B) shows that the
E155G mutation is more severe than Y99C, in that the
failure to inhibit activity at high [Ca2]free is more
pronounced.
Discussion
A novel E155G mutation in GUCA1A, the gene encod-
ing GCAP1, has been identified in a family affected by
autosomal dominant cone dystrophy (COD3). A total
of three disease-associated mutations, including this one,
have been reported inGUCA1A, the other two involving
Y99C (Payne et al. 1998) and P50L substitutions
(Downes et al. 2001). All three disorders may present
with a clinical diagnosis of cone dystrophy, but they
differ in severity. E155G is similar to Y99C, in that it
causes a severe phenotype. However, the mean age at
onset of disease (16 years) is noticeably earlier in patients
with E155G than in patients with Y99C, who do not
have clinical symptoms until at least the third decade of
life. In contrast, P50L is associated with a generally less-
severe, but markedly variable, phenotype. This study
allows us to address the question of how the identity of
different mutations in the same gene results in variable
expressivity of the disease.
The E155G mutation occurs within the fourth EF-
hand domain of GCAP1. EF-hand domains comprise
a helix-loop-helix motif, the loop region of which
consists of 12 residues. Several of these residues are
involved in coordinating the Ca2 ion via oxygen-
containing side chains and are frequently glutamate
or aspartate. Within functional EF-hand domains, an
invariantglutamate residue is found at position 12,
which has been shown to be essential for Ca2 coordina-
tion (Kretsinger 1976). It is this highly conserved residue
of EF4 that is mutated in the patients in this family
affected with dominant cone dystrophy.
X-ray crystallographic models of EF hands in a num-
ber of calcium-binding proteins have shown that each
calcium ion coordinates seven oxygen ligands (Stry-
nadka and James 1989). One of these oxygen ligands
is provided by a water molecule, and the remaining six
are provided by oxygen-containing side chains of resi-
dues in the loop. The glutamate at position 12 contrib-
utes both of its side-chain oxygen atoms to the metal-
ion coordination (i.e., it is bidentate), but the remaining
four ligands are monodentate. Thus, substitution of
Glu155 in EF4 by a glycine residue, with no oxygen-
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Figure 6 Model structure of GCAP1 showing the overall fold
of the molecule. A, Complete structure, showing helices (blue) and
loops (yellow). The key residues determining the calcium-binding abil-
ity of each EF hand are shown in space-filling mode and are labeled.
The EF1 hand, which is predicted to be incapable of binding calcium,
is shown in orange, to distinguish it from the calcium-binding EFhands
2–4 (green). Amino acid residues 50, 99, and 155, which correspond
to the detected mutations in GCAP1, are shown in pink. The figure
was produced using SETOR (Evans 1993). B, Enlargement of the EF4
domain, showing the polypeptide backbone in ribbon form (blue) and
the five amino acid side chains, including E155, that assist in calcium
coordination (black). The Ca2 ion is shown as a red circle. The figure
was produced using Swiss-Model (Peitsch 1996).
containing side chain, effectively reduces the number of
coordinating oxygen ligands from seven to five. As the
results presented here reveal, this has a drastic effect on
calcium binding.
A pictorial representation of a model of GCAP1 is
shown in figure 6A. This highlights the positions of the
EF hands and the positions of the E155G mutation and
the two previously reportedmutations, Y99C and P50L.
The enlargement of the EF4 domain (fig. 6B) shows the
positions of the five amino acid side chains (D144,
N146, D148, S152, and E155) that assist in calcium
coordination. Note that there is another glutamate res-
idue in the loop, E150, but this points away from the
calcium ion and does not appear to contribute to metal
binding.
The E155Gmutation, like the Y99Cmutation, results
in constitutive activation of RetGC1 at physiologically
high [Ca2]free, although the severity of the effect is some-
what greater than that produced by Y99C. Consistent
with this observation, the onset of disease is earliest in
patients with the E155G mutation. The E155G muta-
tion also results in a reduced apparent affinity of the
protein for RetGC1, an effect not observed with the
Y99C mutant. Both these effects have been shown to
persist in the presence of wild-type GCAP1 and thus act
in a dominant manner. The consequence, in the cell, of
the reduced apparent affinity for RetGC1 is difficult to
assess, since the prevailing concentrations of both
GCAP1 and RetGC1 are unknown. On the other hand,
the constitutive activation of RetGC1 would be ex-
pected to result in a persistently elevated level of cGMP
in the cell, above that required to keep the cGMP-gated
cation channels open, resulting in maintenance of high
[Ca2]free. The mechanism of the ensuing photoreceptor
degeneration is unclear, but it is known that persistently
elevated calcium levels tend to disrupt the membrane
potential of the mitochondrial outer membrane, leading
to release of cytochrome c, with subsequent caspase
activation and apoptosis (Green and Reed 1998). Pre-
vious studies have also linked elevated cGMP levels,
arising from mutations in the phosphodiesterase gene,
to cell death (Pittler and Baehr 1991; Farber et al. 1992).
Why mutations in GCAP1 result in selective cone de-
generation with preservation of rod function is unclear.
Cytohistochemical studies have indicated that the con-
centrations of both RetGC1 and GCAP1 are higher in
cone photoreceptors than in rod photoreceptors (Liu et
al. 1994; Kachi et al. 1999). Thus, a mutation in GCAP1
that affects the cyclase activity might be expected to
cause a more serious imbalance in cones than in rods.
However, mutations in the GUCY2D gene, encoding
RetGC1, which also result in constitutive RetGC1 ac-
tivity, have been linked to cone-rod dystrophy (Kelsell
et al. 1998; Perrault et al. 1998; Weigell-Weber et al.
2000; Wilkie et al. 2000). It is therefore difficult to
explain why severe mutations in GCAP1 with similar
functional consequences do not also affect the rods. One
difference in the effects of the mutations is that the cone-
rod mutations in RetGC1 lead to an increased apparent
affinity for GCAP1, but the E155G mutation in GCAP1
leads to a decrease in this property. An increased ap-
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parent affinity of the cyclase for GCAP1 will tend to
exacerbate the failure to abolish cyclase activation at
high levels of [Ca2]free, but a reduced apparent affinity
should compensate for it. In this way, the overall se-
verity of the effect of the E155G mutation may be less-
ened in comparison with the RetGC1 mutations, with
the sparing of the rods.
Rudnicka-Nawrot et al. (1998) have examined the
effects of inactivation of individual EF hands on the
function of bovine GCAP1 in vitro. This was accom-
plished through the substitution of glutamate with as-
partate (conserving the negative charge) at position 12
of the three functional EF motifs in GCAP1, thus al-
tering the affinity of the domains for Ca2 without dis-
rupting their structure. Rudnicka-Nawrot et al. dem-
onstrated that only EF3 and EF4 contribute to the
Ca2-dependent inhibition of RetGC1 by GCAP1. The
mutants with a single substitution, E111D or E155D,
resulted in ∼50% inhibition of cyclase activity at a
[Ca2]free of 500 mM, but double mutants (E111D and
E155D) and triple mutants (E75D, E111D, and E155D)
activated cGMP synthesis in a manner completely in-
dependent of [Ca2]free. In contrast, the results presented
here demonstrate that the nonconservative substitution
of the position 12 glutamate by the small neutral residue
glycine has a more drastic effect on calcium binding,
with the consequence that a single mutation in EF4
results in !25% inhibition of the cyclase activity at a
calcium concentration of 500 mM.
Finally, an understanding of the functional effects
of GCAP1 mutations on signaling within the photo-
receptor is important, not only for the elucidation of
the pathophysiology of these cone dystrophies but
also, in view of the sequence similarity and conserved
structural domains of all NCBPs, for the study of
the pathogenesis of retinal dystrophies arising frommu-
tations in other intracellular Ca2- and cGMP-mediated
signaling systems.
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